Visually discernible myocardial echocardiographic contrast after intravenous injection of sonicated dextrose albumin microbubbles containing high molecular weight, less soluble gases

Section of Cardiology, University of Nebraska Medical Center, Omaha 68198-2265.

OBJECTIVES. The central hypothesis of this study was that microbubble survival, and subsequent left ventricular and myocardial ultrasound contrast, could be improved by altering microbubble gas to consist of a higher molecular weight (less diffusible) and less soluble gas. BACKGROUND. Microbubble survival after intravenous injection is shortened because of rapid diffusion of blood-soluble room air gases (nitrogen and oxygen) across the permeable bubble membrane into blood. METHODS. Thirteen open chest dogs received intravenous injections of a constant dose of sonicated dextrose albumin that was incubated with either room air or 100% nitrogen, 100% helium or 100% sulfur hexafluoride. Nitrogen (100%) is less blood soluble than room air, whereas helium and sulfur hexafluoride are the least soluble. Sulfur hexafluoride has the slowest diffusion rate. To further decrease the diffusion rate, each sample was administered during inhalation of room air and again during brief inhalation of the same gas with which it had been incubated. RESULTS. The highest peak videointensity in the left ventricular cavity was produced by the sonicated dextrose albumin incubated with sulfur hexafluoride, the gas having lowest blood solubility and diffusion rate, while sulfur hexafluoride was briefly inhaled during the period of intravenous injection (peak videointensity 139 +/- 10 vs. 54 +/- 11 for room air-exposed sonicated dextrose albumin, p < 0.001). Myocardial contrast was visually evident in > 80% of the intravenous injections of sulfur hexafluoride-exposed sonicated dextrose albumin when the agent was given as an 8-fold concentrated sample during brief inhalation of sulfur hexafluoride. CONCLUSIONS. Visual myocardial echocardiographic contrast is possible after intravenous injection of sonicated dextrose albumin if the microbubbles contain a gas with low blood solubility and diffusivity.

This article has been cited by other articles:

				M. L. Main, J. H. Goldman, and P. A. Grayburn Thinking Outside the "Box" The Ultrasound Contrast Controversy J. Am. Coll. Cardiol., December 18, 2007; 50(25): 2434 - 2437. [Abstract] [Full Text] [PDF]

				D. Vancraeynest, X. Havaux, A.-C. Pouleur, A. Pasquet, B. Gerber, C. Beauloye, P. Rafter, L. Bertrand, and J.-L. J. Vanoverschelde Myocardial delivery of colloid nanoparticles using ultrasound-targeted microbubble destruction Eur. Heart J., January 2, 2006; 27(2): 237 - 245. [Abstract] [Full Text] [PDF]

				S. A. Hayat and R. Senior Safety: The heart of the matter Eur J Echocardiogr, August 1, 2005; 6(4): 235 - 237. [Abstract] [Full Text] [PDF]

				M. Peltier, D. Vancraeynest, A. Pasquet, T. Ay, V. Roelants, A.-M. D'hondt, J. A. Melin, and J.-L. J. Vanoverschelde Assessment of the physiologic significance of coronary disease with dipyridamole real-time myocardial contrast echocardiography: Comparison with technetium-99m sestamibi single-photon emission computed tomography and quantitative coronary angiography J. Am. Coll. Cardiol., January 21, 2004; 43(2): 257 - 264. [Abstract] [Full Text] [PDF]

				T. Ay, X. Havaux, G. Van Camp, B. Campanelli, G. Gisellu, A. Pasquet, J.-F. Denef, J. A. Melin, and J.-L. J. Vanoverschelde Destruction of Contrast Microbubbles by Ultrasound: Effects on Myocardial Function, Coronary Perfusion Pressure, and Microvascular Integrity Circulation, July 24, 2001; 104(4): 461 - 466. [Abstract] [Full Text] [PDF]

				I Jucquois, P Nihoyannopoulos, A-M D'Hondt, V Roelants, A Robert, J A Melin, D Glass, and J-L J Vanoverschelde Comparison of myocardial contrast echocardiography with NC100100 and 99mTc sestamibi SPECT for detection of resting myocardial perfusion abnormalities in patients with previous myocardial infarction Heart, May 1, 2000; 83(5): 518 - 524. [Abstract] [Full Text]

				P. A. Grayburn, J. L. Weiss, T. C. Hack, E. Klodas, J. S. Raichlen, M. A. Vannan, A. L. Klein, D. W. Kitzman, S. G. Chrysant, J. L. Cohen, et al. Phase III multicenter trial comparing the efficacy of 2% dodecafluoropentane emulsion (EchoGen) and sonicated 5% human albumin (Albunex) as ultrasound contrast agents in patients with suboptimal echocardiograms J. Am. Coll. Cardiol., July 1, 1998; 32(1): 230 - 236. [Abstract] [Full Text] [PDF]